2018
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, Ng CKY, Bedard PL, Tortora G, Douillard J, Van Allen EM, Schultz N, Swanton C, André F, Pusztai L. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Annals Of Oncology 2018, 29: 1895-1902. PMID: 30137196, PMCID: PMC6158764, DOI: 10.1093/annonc/mdy263.Peer-Reviewed Original ResearchConceptsESMO ScaleMolecular targetsClinical actionabilityPrecision Medicine Working GroupGenomic alterationsPrecision medicineRoutine clinical decisionEvidence-based criteriaMedicine Working GroupLack of evidencePreclinical evidenceClinical benefitClinical evidencePatient populationClassification systemClinical managementCancer precision medicineInvestigational targetsPatient managementMolecular aberrationsTumor typesClinical decisionClinical targetsAvailable evidenceEuropean Society
2011
Gene expression profiling in breast cancer: classification, prognostication, and prediction
Reis-Filho JS, Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. The Lancet 2011, 378: 1812-1823. PMID: 22098854, DOI: 10.1016/s0140-6736(11)61539-0.Peer-Reviewed Original ResearchConceptsBreast cancerER-negative breast cancerGene expression profilingER-positive diseasePrognosis of patientsDistinct molecular aberrationsMolecular classification systemPotential clinical useClinical behaviorHistological featuresClinical trialsMolecular subtypesProliferation-related genesMultigene classifiersClinical practiceMolecular aberrationsExpression profilingCancerDistinct diseasesMultigene predictorsClinical useMolecular classificationDiseaseHeterogeneous groupDifferent diseases